New Patents Earned by Fox Chase Cancer Center in Fiscal Years 2017 and 2018

Philadelphia (September 28, 2018) – Fox Chase Cancer Center is pleased to announce that its scientists and clinicians earned several newly issued patents during fiscal years 2017 and 2018, the latter of which ended June 30, 2018. The patents, along with the inventors’ names and issue dates, are listed below.

Astsaturov Igor, Khazak Vladimir, and Serebriiski Ilya, “Method of treating MYC-amplified tumors with RNA-polymerase II inhibitors”, US Patent# 9,993,458 B2, issued Jun 12, 2018  

Borghaei Hossein and Weiner Louis M., “Antibodies to Tumor Endothelial Marker 7R”, US Patent# 9,534,050 B2, issued Jan 03, 2017

Adams Gregory P., Simmons Heidi H., Robinson Matthew K., Dunbrack Roland, and Lehmann Andreas, “Rationally-designed anti-mullerian inhibiting substance type II receptor antibodies” US Patent# 9,611,321 B2, issued Apr 04, 2017

Hensley Harvey and Roder Navid, “Systems for fusion of fluorescence molecular tomography and magnetic resonance images”, US Patent# 9,629,549 B2, issued Apr 25, 2017

Skalka Anna Marie, Andrake Mark, and  Bojja Ravi Shankar, ” Inhibition of human immunodeficiency virus integrase reaching dimer formation utilizing single-chain variable antibodies”, US Patent# 9,533,040 B2, issued Jan 03, 2017

Yang Zeng-Jie, “Inhibition of leukotriene synthesis and activity in the treatment of sonic hedgehog-associated medulloblastoma”, US Patent# 9,616,056 B2 issued Apr 11, 2017

Yen Timothy and Bhattacharjee Vikram, “Combined Inhibition of the Vitamin D Receptor and Poly(ADP)Ribose Polymerase (PARP) in the Treatment of Cancer”, US Patent# 9,889,141 B2 issued on Feb 13, 2018

Fox Chase Cancer Center (Fox Chase), which includes the Institute for Cancer Research and the American Oncologic Hospital and is a part of Temple Health, is one of the leading comprehensive cancer centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase is also one of just 10 members of the Alliance of Dedicated Cancer Centers. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence six consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

For more information, call 888-369-2427